Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namilumab vs Adalimumab in Early Rheumatoid Arthritis
NCT02393378Phase 2Terminated
- Sponsor
- Takeda
- Start
- Apr 2015
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of namilumab in rheumatoid arthritis (RA), sponsored by Takeda. Started Apr 2015; status: terminated.
02
Drugs
namilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02393378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02393378.